Power Law company profile

Ra Pharmaceuticals

Biotech & Life Sciences · Cambridge, United States · Founded 2008 · IPO 2016 Unicorn

Ra Pharma is developing Cyclomimetics™, a new drug class combining the properties and benefits of antibodies and small molecules

Valuation

$2.30B

Market cap · 2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

8 investors on Ra Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 8 investors entered at this stage

Rock Springs Capital

RA Capital Management

Morgenthaler Ventures

Lightstone Ventures

NEA

Novartis Venture Fund

Amgen Ventures

Novo Ventures

Global footprint

Where Ra Pharmaceuticals has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Patent intelligence

$30M patent portfolio · 18 active families

Estimated portfolio value

$30M

1.3% of market cap · 9.1× smaller than top peer argenx ($275M)

18 active patent families

Where Ra Pharmaceuticals innovates Molecular biologyComplement activityBiochemistryCell biologyPharmacology

Where Ra Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Ra Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Ra Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Ra Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ra Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles